Innovation to Impact (i2I) Grants
The Canadian Cancer Society’s Innovation to Impact (i2I) Grants support investigators in advancing productive findings from completed CCS Innovation or CBCF research grants toward meaningful cancer impacts—funding “logical next steps” in pre-clinical, translational, or early clinical research.
Eligibility Criteria:
-
Principal Investigator or Co-Investigator on a CCS Innovation Grant (including Prevention Innovation) or CBCF Grant that ended between January 1, 2017 and October 31, 2020.
-
Must demonstrate significant achievements from the original grant (e.g., publications, IP, technology development) and clearly link the i2I proposal to the overarching objectives of that grant.
-
Unexpected or serendipitous findings from the original grant are eligible if sufficient preliminary data support the proposed follow-on work.
Funding Details:
-
Amount: Up to 150,000 CAD per year (direct costs only), for a maximum of 3 years.
-
Use of Funds: Research supplies, salaries, small equipment (≤ $50,000 per grant, exceptions considered for platform/dev technology), and related project expenses.
-
Exclusions: Indirect costs; salaries for major equipment operators; large instruments beyond $50K without strong justification.
Deadline:
Not currently active—application window closed. (For reference, applicants submitted full proposals via EGrAMS when the program was offered.)
Where to Go for Further Information:
Archived application guides and panel descriptions available on the CCS EGrAMS documentation site.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023